{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:07:19Z","timestamp":1785366439825,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200464"],"award-info":[{"award-number":["RP200464"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA269002"],"award-info":[{"award-number":["R01 CA269002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007144","name":"University of Houston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007144","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.canlet.2024.217319","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T23:46:33Z","timestamp":1730504793000},"page":"217319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors"],"prefix":"10.1016","volume":"608","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-9021","authenticated-orcid":false,"given":"Yan-ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0576-6362","authenticated-orcid":false,"given":"Jane Jing","family":"Ting Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun Xiaoliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217319_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2024.217319_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217319_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216871","article-title":"The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors","volume":"591","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.canlet.2024.217319_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1515\/mr-2022-0033","article-title":"Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives","volume":"2","author":"Liu","year":"2022","journal-title":"Medical Rev."},{"key":"10.1016\/j.canlet.2024.217319_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug conjugate-based anticancer therapy - current status and perspectives","volume":"552","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217319_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217319_bib10","doi-asserted-by":"crossref","first-page":"15177","DOI":"10.1021\/bi970147b","article-title":"Spontaneous, pH-dependent membrane insertion of a transbilayer alpha-helix","volume":"36","author":"Hunt","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2024.217319_bib11","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1073\/pnas.0702439104","article-title":"Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo","volume":"104","author":"Andreev","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.217319_bib12","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1529\/biophysj.107.109967","article-title":"A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers","volume":"93","author":"Reshetnyak","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.canlet.2024.217319_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030541","article-title":"Targeting the hypoxic and acidic tumor microenvironment with pH-sensitive peptides","volume":"10","author":"Dharmaratne","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.217319_bib14","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1158\/0008-5472.CAN-08-3781","article-title":"A novel technology for the imaging of acidic prostate tumors by positron emission tomography","volume":"69","author":"V\u0101vere","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217319_bib15","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s11307-010-0457-z","article-title":"Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP","volume":"13","author":"Reshetnyak","year":"2011","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.canlet.2024.217319_bib16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/bc3000222","article-title":"Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation","volume":"23","author":"Daumar","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.canlet.2024.217319_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1073\/pnas.1219665110","article-title":"pHLIP peptide targets nanogold particles to tumors","volume":"110","author":"Yao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.217319_bib18","doi-asserted-by":"crossref","first-page":"20246","DOI":"10.1073\/pnas.1014403107","article-title":"pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation","volume":"107","author":"An","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2024.217319_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1021\/bi301647y","article-title":"Antiproliferative effect of pHLIP-amanitin","volume":"52","author":"Moshnikova","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2024.217319_bib20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/mp500779k","article-title":"Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates","volume":"12","author":"Burns","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2024.217319_bib21","first-page":"1734","article-title":"A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7\/Adr cells","volume":"23","author":"Song","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.canlet.2024.217319_bib22","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1002\/anie.201409770","article-title":"Noncanonical amino acids to improve the pH response of pHLIP insertion at tumor acidity","volume":"54","author":"Onyango","year":"2015","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.canlet.2024.217319_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13905","article-title":"MicroRNA silencing for cancer therapy targeted to the tumour microenvironment","volume":"518","author":"Cheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217319_bib24","first-page":"461","article-title":"Tumor-targeted, cytoplasmic delivery of large, polar molecules using a pH-low insertion peptide","volume":"17","author":"Svoronos","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.canlet.2024.217319_bib25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1541-7786.MCR-19-0661","article-title":"Ku80-Targeted pH-sensitive peptide-PNA conjugates are tumor selective and sensitize cancer cells to ionizing radiation","volume":"18","author":"Kaplan","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217319_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2013.01.037","article-title":"pHLIP\u00ae-mediated delivery of PEGylated liposomes to cancer cells","volume":"167","author":"Yao","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.217319_bib27","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1038\/srep03560","article-title":"pH dependent transfer of nano-pores into membrane of cancer cells to induce apoptosis","volume":"3","author":"Wijesinghe","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217319_bib28","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/ijc.28269","article-title":"Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery","volume":"133","author":"Fu","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217319_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-5793(97)00983-6","article-title":"Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: the VH domain has an extended CDR-H3 and exhibits unusual solubility","volume":"414","author":"Schiweck","year":"1997","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib30","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1529\/biophysj.107.109967","article-title":"A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers","volume":"93","author":"Reshetnyak","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.canlet.2024.217319_bib31","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.0601463103","article-title":"Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix","volume":"103","author":"Reshetnyak","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.217319_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/IJGC:29:1:37","article-title":"A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy","volume":"29","author":"Wang","year":"2001","journal-title":"Int. J. Gastrointest. Cancer"},{"key":"10.1016\/j.canlet.2024.217319_bib33","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1021\/acs.jmedchem.0c00016","article-title":"pH-dependent grafting of cancer cells with antigenic epitopes promotes selective antibody-mediated cytotoxicity","volume":"63","author":"Wehr","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.217319_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nature07017","article-title":"Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate","volume":"453","author":"Gallagher","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217319_bib35","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1073\/pnas.1608247113","article-title":"Probe for the measurement of cell surface pH in vivo and ex vivo","volume":"113","author":"Anderson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.217319_bib36","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.1021\/bi2009773","article-title":"Tuning a polar molecule for selective cytoplasmic delivery by a pH (low) insertion peptide","volume":"50","author":"Wijesinghe","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2024.217319_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/1097-0320(20001201)41:4<289::AID-CYTO7>3.0.CO;2-5","article-title":"Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species","volume":"41","author":"Piriou","year":"2000","journal-title":"Cytometry"},{"key":"10.1016\/j.canlet.2024.217319_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217319_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2014 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217319_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dot.2005.41.2.882662","article-title":"Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody","volume":"41","author":"Harding","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.canlet.2024.217319_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","article-title":"Predictive biomarkers: a paradigm shift towards personalized cancer medicine","volume":"8","author":"La Thangue","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217319_bib42","doi-asserted-by":"crossref","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.217319_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.30767","article-title":"ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody","volume":"141","author":"Jochems","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217319_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2024.217319_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/eji.202149766","article-title":"Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species","volume":"52","author":"Wang","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2024.217319_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217083","article-title":"The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the Sphinx?","volume":"597","author":"Zhou","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.217319_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.217319_bib49","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","article-title":"Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR","volume":"7","author":"Zhang","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2024.217319_bib50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217319_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216279","article-title":"Cancer-associated fibroblasts: a key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma","volume":"567","author":"Luo","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.217319_bib52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00424-022-02696-6","article-title":"Kidney metabolism and acid\u2013base control: back to the basics","volume":"474","author":"Imenez Silva","year":"2022","journal-title":"Pflueg. Arch. Eur. J. Physiol."},{"key":"10.1016\/j.canlet.2024.217319_bib53","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217319_bib54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217319_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.217319_bib56","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor Action1","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217319_bib57","first-page":"3384","article-title":"Tumor-inhibitory antibodies to HER-2\/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2","volume":"60","author":"Klapper","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217319_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217319_bib59","first-page":"25","article-title":"Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR\/HER-2 heterodimerization and activation","volume":"34","author":"Patel","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2024.217319_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524007146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:34:21Z","timestamp":1733499261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524007146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"alternative-id":["S0304383524007146"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217319","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217319"}}